Comparing vericiguat with standard care for heart failure
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether adding a new medicine called vericiguat to standard heart failure treatments helps patients with heart failure feel better and avoid hospital stays. Vericiguat is a pill that may improve heart function and reduce symptoms like shortness of breath and fatigue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have chronic heart failure with reduced pumping ability (ejection fraction less than 45%).
- You have had symptoms like shortness of breath or fatigue in the past month (NYHA class II, III, or IV).
- You have elevated BNP or NT-proBNP levels (a blood test that shows heart strain).
- You have had a recent worsening of your heart failure symptoms.
- You are already on standard heart failure medications for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called vericiguat (a pill) to see if it can improve the heart's shape and function in people with heart failure and a weakened pump. You would keep taking your usual heart medications plus the study drug.
This trial tests an investigational medicine called CRD-4730 (taken as a pill) to see if it can improve heart function and symptoms in people with heart failure and a reduced pumping ability. It may help you feel better and slow the progression of your condition.
This study tests whether the drug vericiguat helps people with heart failure after a heart attack. The trial looks at people whose heart pumping is weak and who have symptoms despite standard treatment.
This trial tests how a medication called vericiguat works in people with both chronic kidney disease and heart failure. It aims to see if the drug helps manage these conditions together.
This trial tests if adding vericiguat to standard heart failure medicines helps people hospitalized with worsening heart failure. It's for those with a weak heart pump and high NT-proBNP levels.
This study checks how safe the medicine vericiguat is for Japanese people with chronic heart failure when used in everyday care. It compares patients who receive vericiguat with patients who continue standard treatments without vericiguat.
Hear when a new Heart Failure With Reduced Ejection Fraction (HFrEF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.